Longitudinal Magnetic Resonance Imaging Study of Perfusion and Diffusion in Stroke:Evolution of Lesion Volume and Correlation with Clinical Outcome
Ann Neurol 46:568-578,556, Beaulieu,C.,et al, 1999
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Quantitative MRI in Patients with Clinically Isolated Syndromes Suggestive of Demyelination
Neurol 52:599-606, Sailer,M.,et al, 1999
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Longitudinal MRI in Multiple Sclerosis:Correlation Between Disability and Lesion Burden
Neurol 44:2120-2124, Khoury,S.J.,et al, 1994